Management of Iron Overload in Infants and Toddlers With Diamond–Blackfan Anemia Syndrome: A French–Italian Study
Diamond-Blackfan Anemia Syndrome (DBAS) is a rare congenital anemia often requiring chronic red blood cell transfusions from infancy. Without appropriate chelation, iron overload develops early and may be severe; however, no data are available on chelation in patients under 3 years of age. To address this, we conducted a retrospective, multicenter study collecting data from the French and Italian DBAS national registries. A total of 167 transfused DBAS patients were screened. Of these, 64 (38%) initiated chelation before the age of three (median: 18 months). Indications for chelation were a serum ferritin ≥ 500 ng/mL (median: 1340 ng/mL) and more than 10 transfusions. Deferasirox was the most frequently used chelator (63%), followed by deferoxamine (35%). Chelation was associated with a significant reduction in serum ferritin levels (-11% per year; p < 0.001). At 5-6 years of age, ferritin level was available for 28 patients: 43% had levels < 500 ng/mL, and none exceeded 2000 ng/mL. Liver iron concentration was assessed in 31/64 patients (48%) at a median age of 3.2 years; 45% showed severe overload at first evaluation. Among 22 patients who underwent cardiac magnetic resonance, no myocardial iron overload was detected. These real-world data support the feasibility, tolerability, and effectiveness of chelation in transfusion-dependent DBAS patients under 3 years, allowing prevention of cardiac iron overload. Although derived from DBAS, these findings may inform the management of iron overload in infants and toddlers with other transfusion-dependent anemias and support development of age-specific chelation strategies.
Authors
- Anne Sîrvent (ORCID: https://orcid.org/0000-0002-8976-7018)
- Maria Licciardello
- Adriana Carando
- Nathalie Garnier (ORCID: https://orcid.org/0000-0001-6274-8928)
- Emanuela Garelli
- Elisa Bertoni
- F Fagioli
- Coralie Mallebranche (ORCID: https://orcid.org/0000-0002-8385-4057)
- Marco Zecca (ORCID: https://orcid.org/0000-0002-8818-1744)
- Thierry Leblanc (ORCID: https://orcid.org/0000-0003-2463-9346)
- Antonella Sau
- Arthur Sterin
- Marie‐Pierre Castex
- Francesca Torchio
- Paola Quarello
- Nathalie Aladjidi
- Isabelle Marie
- Lydie M. Da Costa
- Baptiste Lecalvez
- Benedicte Bruno (ORCID: https://orcid.org/0000-0002-6453-6395)
Institutions
- Centre National de la Recherche Scientifique (FR)
- Inserm (FR)
- Université Paris Cité (FR)
- Université Paris-Saclay (FR)
- Institut Gustave Roussy (FR)
- Saint Louis University Hospital (US)
- University of Catania (IT)
- Institut d’Hématologie et d’Oncologie Pédiatrique (FR)
- Centre de Recherche en Cancérologie et Immunologie Intégrée Nantes Angers (FR)
- Centre Hospitalier Universitaire de Montpellier (FR)
- Azienda Socio Sanitaria Territoriale degli Spedali Civili di Brescia (IT)
- Hôpital Jeanne de Flandre (FR)
- Ospedale di Santo Spirito (IT)
- Laboratoire National de Référence (MA)
- Hôpital Pellegrin (FR)
- Centre Hospitalier Universitaire d'Angers (FR)
- Hôpital Robert-Debré (FR)
- Ospedale Regina Margherita (IT)
- Hôpital Saint-Louis (FR)
- Hôpital des Enfants (FR)
- Policlinico San Matteo Fondazione (IT)
- Istituti di Ricovero e Cura a Carattere Scientifico (IT)
- Department of Public Health (US)
- Hôpital de la Timone (FR)
- Bicêtre Hospital (FR)
- Université d'Angers (FR)
- University of Turin (IT)
Publication Details
- Journal
- American Journal of Hematology
- Published
- 2026-05-11
- DOI
- https://doi.org/10.1002/ajh.70354
- Primary Topic
- RNA modifications and cancer
- Type
- article
- Field-Weighted Citation Impact
- 0.00